Biliary tract cancer is an aggressive gastrointestinal malignancy with a dismal prognosis. Combined chemotherapy with gemcitabine and cisplatin is the gold standard of first-line treatment for patients with advanced biliary tract cancer, while second-line therapy remains inconclusive. We aimed to evaluate the effects of apatinib as a second-line regimen in patients with advanced biliary tract cancer. We retrospectively analyzed 18 patients with advanced biliary tract cancer who failed first-line therapy with gemcitabine alone or gemcitabine combined with cisplatin and received second-line treatment with apatinib from June 2016 to October 2017. Adverse events, progression-free survival, objective response rate, and disease control rate were documented and evaluated. All patients were followed up until progression of the disease.
Introduction
Biliary tract cancer (BTC) is a lethal malignancy encompassing gallbladder carcinoma and cholangiocarcinoma.
The latter is further subdivided into intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma [1] . Though it is less common in the Western world, where the annual incidence is 0.35 to 2 per 100,000, the prevalence in Hispanic and Asian populations is much higher [2] . For instance, the incidence may be up 40-fold higher in China than in the United Kingdom [3, 4] .
At present, a satisfactory outcome of BTC hinges on early diagnosis and complete surgical resection. However, due to its slow-growing nature and non-specific symptomatology, BTC is often diagnosed at an advanced stage when surgical options are limited [5, 6] . Even in patients undergoing successful resection, recurrence rates may reach 49-64%, and most cases will eventually progress to metastatic disease, which highlighting the importance of advancing adjuvant therapies [7] [8] [9] .
According to the guideline of the National Comprehensive Cancer Network, Version 2.2019, standard first-line chemotherapeutic regimens for BTC include gemcitabine-based or gemcitabine-cisplatin combination therapy for the metastatic or unresectable disease [10] . However, no clear guidance exists for second-line treatment following disease progression under first-line chemotherapy. Many clinical trials are currently being conducted to evaluate the efficacy of a multitude of agents targeting the molecular level in second-line settings [11] . However, the results of these trials have not yet been published. Angiogenesis, a physiological process through which new blood vessels form from pre-existing vessels is responsible for tumor growth and disease progression [12, 13] . In recent years, anti-angiogenic treatment has become an essential tool in the armamentarium against advanced cancers. Vascular endothelial growth factor (VEGF) and its cognate receptor, VEGFR-2 is recognized as the most prominent regulators of angiogenesis [14] , and have therefore become the main target of current antiangiogenic agents.
Thus, strategies focus on antiangiogenesis therapy via VEGF pathway inhibition might have clinical benefits in the treatment of patients with advanced BTC [15] . A number of agents targeting the VEGF/VEGFR signaling pathway, including bevacizumab, aflibercept, and ramucirumab, have been developed and approved for several indications by the U.S. Food and Drug Administration [13] . VEGF is over expressed in 40-75% of patients with BTC [16] . In a phase II trial, bevacizumab was added to second-line chemotherapy for advanced BTC and reported to have a modest benefit as well as a tolerable safety profile [17] . Moreover, in another phase II trial of treatment of advanced BTC, ramu-cirumab showed limited activity but still infrequent grade 3-4 treatment-related adverse events (AEs) when combined with pembrolizumab in a second-line setting [18] .
Apatinib is an oral tyrosine kinase inhibitor selectively inhibiting VEGFR-2, thereby suppressing tumor growth by obstructing angiogenesis. It has been approved in China for advanced or metastatic gastric cancer and has shown promising therapeutic effects against a variety of other cancer types, including ovarian cancer [19] , breast cancer [20] [21] [22] , lung cancer [23, 24] , hepatocellular carcinoma [25] [26] [27] , sarcoma [28] [29] [30] , and thyroid cancer [31, 32] . Nevertheless, research evaluating the effect of apatinib on advanced BTC is limited. As a broad-spectrum anticancer agent, apatinib has been a frequent option for patients with advanced BTC after first-line treatment failure in our hospital at the discretion of the treating physicians and showed favorable effects.
In the present study, we hypothesized that apatinib is an effective second-line regimen for the treatment of patients with advanced BTC. Therefore, we retrospectively assessed the effects of apatinib monotherapy in a second-line setting after the failure of first-line systemic chemotherapy with gemcitabine or gemcitabine-cisplatin in patients with advanced BTC. 98
Patients and Methods

Eligibility criteria
The study was conducted retrospectively on patients 
Treatment Methods
Following disease progression after first-line treatment, patients were offered apatinib at a dose of 500 mg once daily until disease progression or intolerable. One dose reduction (to 250 mg) due to drug-related toxicity was allowed. Dose-limiting toxicity was defined as possibly or definitely drug-related grades 3-4 toxic responses. Apatinib was provided by Jiangsu Hengrui Medicine Co., Ltd and was administered orally. One treatment cycle was 28 days long.
Evaluation of efficacy and safety
Clinical and radiologic evaluations were conducted at baseline and at 1 month; thereafter every 2 months or when- A schematic illustration of the study overview is shown in Figure   1 .
Category
Definition Complete response (CR) Complete disappearance of all target lesions Partial response (PR) ≥30 % decrease in tumor diameter from baseline Stable disease (SD)
Small changes that do not meet the above criteria Progressive disease (PD) >20% increase in tumor diameter from baseline Eight cases (44%) were post-surgery recurrence, while the other 10 (56%) were initially diagnosed, patients. All patients started apatinib at a dosage of 500 mg; in 6 patients (33%), the apatinib dose was reduced to 250 mg daily within the first10 days due to intolerable toxicity. The median PFS was 8 months for the whole population; it was 2.5 months for gallbladder carcinoma and 8 months for cholangiocarcinoma. Kaplan-Meier curve for PFS presenting the whole cohort is depicted in Figure 2A ; Figure 2B 
Evaluation of efficacy
Discussion
To our knowledge, this is the first study evaluating the efficacy and safety profile of apatinib as a second-line treatment in patients with advanced BTC. The median PFS was 8 months, while the 1-month ORR was 33% and DCR was 72%, the 6-month DCR was 44%. Furthermore, apatinib had a manageable toxicity profile.
Even though surgery is potentially curative, BTC has a high recurrence rate due to its aggressive nature. The vast majority of patients therefore also received systemic chemotherapy,
where the current standard therapy is gemcitabine plus cisplatin and P13K/AKT pathways [37] . Furthermore, in a case report, apatinib was used for a 23-year-old female with advanced unresectable intrahepatic cholangiocarcinoma as second-line treatment and a PFS of 6 months were observed [38] .
To further study the response to apatinib, we retrospectively analyzed the safety and efficacy data of apatinib as a second-line regimen in patients with advanced BTC, revealing a median PFS of 8 months. In the present study, the outcome of apatinib monotherapy was associated with a longer median PFS time than what has previously been reported with chemotherapy [34, 35, 39] , and our findings mirror the above-mentioned result from the case report [38] . This indicates that targeted therapy, especially with agents targeting VEGF pathway, might constitute a breakthrough in establishing a second-line treatment for advanced BTC.
Though both cholangiocarcinoma and gallbladder carcinoma fall under BTC, they may be in fact distinct diseases with differences in prognosis and patterns of recurrence [40] .
Additionally, immunohistochemical analysis for BTC samples has revealed the tumor somatic variants and genomic heterogeneity between the two diseases [41] . In this study, cholangiocarcinoma seemed more responsive to apatinib monotherapy than gallbladder carcinoma, as the median PFS was 8 months in patients with cholangiocarcinoma compared with 2.5 months in patients with gallbladder carcinoma. The arbitrary significance level was not fully reached (P=0.0502). Still, cholangiocarcinoma showed a clear tendency towards a better survival outcome than gallbladder carcinoma, which deserves more indepth studies to determine the underlying mechanism.
Previous studies with VEGF inhibitors across a variety of tumor types established a set of AEs attributed to antiangiogenic therapy, the most well-documented of which were hypertension, arterial thromboembolic events, proteinuria, bowel perforation, reversible posterior leukoencephalopathy syndrome wound complications, and hemorrhage [13, 42] . In the present study, the majority of treatment-related AEs were fatigue, hypertension, proteinuria, diarrhea, and hand-foot syndrome, which is consistent with prior findings. We found somewhat higher rates of grade 3 AEs (9 cases) than previous studies and it ' remains important for efficacy prediction. Another limitation is the absence of a control group to control for confounding from external factors. Therefore, large, well-designed, randomized controlled trials are needed to confirm these results.
In conclusion, the results of the present study reinforce the hypothesis that apatinib may have the potential to act as an effective second-line agent in the treatment of advanced BTC with a manageable safety profile. However, further randomized controlled studies are needed to verify the results obtained from this single-center, retrospective study. 
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